A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo-Reference-Cited by-同舟云学术

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

Published:2015-08-26 Issue:302 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Saunders Laura R.¹,Bankovich Alexander J.¹,Anderson Wade C.¹,Aujay Monette A.¹,Bheddah Sheila¹,Black KristenAnn¹,Desai Radhika¹,Escarpe Paul A.¹,Hampl Johannes¹,Laysang Amy¹,Liu David¹,Lopez-Molina Javier¹,Milton Milly¹,Park Albert¹,Pysz Marybeth A.¹,Shao Hui¹,Slingerland Brian¹,Torgov Michael¹,Williams Samuel A.¹,Foord Orit¹,Howard Philip²,Jassem Jacek³,Badzio Andrzej³,Czapiewski Piotr³,Harpole David H.⁴,Dowlati Afshin⁵,Massion Pierre P.⁶,Travis William D.⁷,Pietanza M. Catherine⁷⁸,Poirier J. T.⁷⁸,Rudin Charles M.⁷,Stull Robert A.¹,Dylla Scott J.¹

Affiliation:

1. Stemcentrx Inc., South San Francisco, CA 94080, USA.

2. Spirogen (a member of the AstraZeneca Group), London W2 6BD, UK.

3. Medical University of Gdańsk, Gdańsk 82-300, Poland.

4. Duke University Medical Cancer, Durham, NC 27710, USA.

5. Case Western Reserve University and University Hospitals Seidman Cancer Center, Cleveland, OH 44106, USA.

6. Thoracic Program, Vanderbilt-Ingram Cancer Center, Tennessee Valley Healthcare Systems, Nashville Campus, Nashville, TN 37232, USA.

7. Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

8. Weill Cornell Medical College, New York, NY 10065, USA.

Abstract

Targeting DLL3 with an antibody-drug conjugate eliminates tumor-initiating cells in high-grade pulmonary neuroendocrine cancers.

Funder